Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A recurrence risk prediction model and recurrence patterns in pulmonary lymphoepithelial carcinoma based on clinical and dynamic hematologic parameters.

Translational lung cancer research·2026
Same author

Development and external validation of a multivariable nomogram for predicting severe immune checkpoint inhibitor-associated myocarditis in advanced lung cancer.

Translational lung cancer research·2026
Same author

First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations.

The New England journal of medicine·2026
Same author

International Consensus on Severe Lung Cancer-The Second Edition.

Translational lung cancer research·2026
Same author

Disrupting SOX2 self-association and condensate formation to overcome chemotherapeutic drug resistance in lung squamous cell carcinoma.

Signal transduction and targeted therapy·2026
Same author

Unraveling the Reciprocal Enhancement Mechanism in a Pd-Gr + BDD Electrochemical System for High-Efficiency Degradation of Tetrabromobisphenol A.

Environmental science & technology·2026

Related Experiment Video

Updated: Aug 8, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004).

Si-Yang Liu1, Qixun Chen2, Chengzhi Zhou3

  • 1Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, People's Republic of China.

Cancer Immunology, Immunotherapy : CII
|March 5, 2023
PubMed
Summary

Neoadjuvant camrelizumab combined with chemotherapy shows promising efficacy and manageable toxicity in non-small cell lung cancer (NSCLC) patients. Further prospective studies are needed to confirm these real-world findings.

Keywords:
CamrelizumabImmune checkpoint inhibitorNeoadjuvantNon-small cell lung cancerReal-world study

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Related Experiment Videos

Last Updated: Aug 8, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Surgery

Background:

  • Camrelizumab demonstrates efficacy in advanced non-small cell lung cancer (NSCLC).
  • Limited data exists on neoadjuvant camrelizumab use in NSCLC.
  • This study addresses the gap in understanding neoadjuvant camrelizumab for NSCLC.

Purpose of the Study:

  • To evaluate the efficacy and safety of neoadjuvant camrelizumab-based therapy in NSCLC patients.
  • To assess treatment response, surgical outcomes, and toxicity in a real-world setting.
  • To provide evidence supporting further investigation of neoadjuvant camrelizumab.

Main Methods:

  • Retrospective review of 96 NSCLC patients receiving neoadjuvant camrelizumab-based therapy and surgery.
  • Data collected included demographics, neoadjuvant treatment details, and surgical information.
  • Analysis of overall response rate, pathological complete response, R0 resection, and postoperative complications.

Main Results:

  • 99% received camrelizumab with chemotherapy; median 2 cycles.
  • High overall response rate (77.1%) and disease control rate (93.8%).
  • Pathological complete response in 27.1%; R0 resection in 93.8%; manageable toxicity (7.3% grade ≥3 AEs).

Conclusions:

  • Neoadjuvant camrelizumab-based therapy shows promising efficacy in NSCLC.
  • The treatment was associated with manageable toxicities in this real-world cohort.
  • Prospective studies are warranted to further validate these findings.